Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

ResMed Inc. (RMD) — XLV Health Care · S&P 500 Profile |瑞思邁公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

ResMed Inc. (RMD) — Business, History & S&P 500 Profile | 瑞思邁公司介紹

ResMed Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #314 · 瑞思邁公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026 (ET)
Financials: FY2026
MARKET CAP
$31.59B
Nov 3, 2026
S&P 500 WEIGHT
0.05%
Rank #314 · Nov 3, 2026
SECTOR RANK
#42
Health Care · Nov 3, 2026
S&P 500 RANK
#314
0.05% · Nov 3, 2026

SNAPSHOT

TickerRMD
CompanyResMed Inc.
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#314 · 0.05% (Nov 3, 2026)
Sector rank#42 in Health Care (Nov 3, 2026)
HeadquartersSan Diego, California
Founded1989
CEOMichael "Mick" Farrell (Chief Executive Officer)
Employees11,370 (2026)
Market cap$31.59B (Nov 3, 2026)
Share price$223.92 (Nov 3, 2026)
SEC filingsEDGAR — CIK 0000943819

WHAT IT DOES

ResMed Inc., headquartered in San Diego, California, is a digital-health and medical-device company built around sleep apnea. It makes the CPAP and APAP flow generators, masks and cloud software used to diagnose and treat sleep-disordered breathing at home, and — through its Residential Care Software business — the software platforms used by home-health, hospice and home-medical-equipment providers.

Its one-line model: sell devices and masks into a diagnosed sleep-apnea population, connect them (every device carries cellular connectivity feeding the AirView and myAir platforms), and layer recurring software revenue on top — fiscal 2026 revenue was $5.65B, split between devices ($2,892M), masks and other accessories ($2,085M) and residential care software ($676M).

ResMed was founded in June 1989 in Australia by Peter C. Farrell to commercialize the CPAP therapy pioneered by Professor Colin Sullivan at the University of Sydney; it opened a San Diego office in 1992, moved its headquarters and incorporation to the United States in 1994, and is dual-listed on the NYSE and the ASX. The founder's son, Michael "Mick" Farrell, has been CEO since March 1, 2013.

BUSINESS SEGMENTS

DevicesCPAP/APAP flow generators and bilevel devices (the AirSense and AirCurve lines) under the Sleep and Breathing Health segment — fiscal 2026 revenue of $2,892M.
Masks & otherPatient interfaces (AirFit masks), accessories and other sleep and respiratory products — fiscal 2026 revenue of $2,085M.
Residential Care SoftwareSaaS platforms for out-of-hospital care — Brightree, MatrixCare and MEDIFOX DAN — reported as its own segment; fiscal 2026 revenue of $676M.

ResMed reports two segments — Sleep and Breathing Health (devices plus masks and other, $4,977M combined in fiscal 2026) and Residential Care Software ($676M). Product lines sum to fiscal 2026 total revenue of $5,653M.

HISTORY

YearMilestone
1989Founded in June 1989 in Australia by Peter C. Farrell, commercializing the continuous positive airway pressure (CPAP) therapy for sleep apnea pioneered by Professor Colin Sullivan at the University of Sydney.
1992Opens a San Diego, California office (1992); headquarters moves to San Diego and the company incorporates in the United States in 1994. It remains dual-listed on the NYSE and the Australian Securities Exchange.
2013Michael "Mick" Farrell, the founder's son, becomes chief executive officer on March 1, 2013.
2016Acquires Brightree for $800M, entering software-as-a-service for home medical equipment providers — the seed of the Residential Care Software segment.
2020During the COVID-19 pandemic, ResMed pivots production to manufacture ventilators and other respiratory devices at scale (hundreds of thousands shipped globally).
2022Acquires MEDIFOX DAN Group in Germany for about $1B, extending Residential Care Software into European out-of-hospital care.

COMPETITIVE POSITION

  • Category leadership in sleep apnea: ResMed and Philips Respironics historically dominate CPAP devices and masks; Philips' multi-year recall (from 2021) shifted share to ResMed.
  • Connected ecosystem: cellular-connected devices feed the AirView clinician platform and myAir patient app, locking in mask-resale and software relationships with home-medical-equipment providers.
  • Software diversification: Residential Care Software (Brightree, MatrixCare, MEDIFOX DAN) adds SaaS revenue less tied to device cycles — $676M in fiscal 2026.
  • Competition set: Philips Respironics, Fisher & Paykel Healthcare, Inspire Medical (implantable therapy) and newer entrants; GLP-1 drugs are a demand-side wildcard (see Risks).

FINANCIAL SNAPSHOT

Total revenue$5.65B (FY2026 revenue)
Operating income$1,887M (FY2026 operating income)
Net income$1,523M (FY2026 net income)
Diluted EPS$10.43 (FY2026 diluted EPS)
Source: ResMed fiscal 2026 results (year ended June 30, 2026) — StockAnalysis financials, compiled from the fiscal 2026 Form 10-K (product-line revenues: devices, masks and other, and residential care software), with headcount corroborated by the Form 10-K itself (approximately 11,370 employees at June 30, 2026).

KEY RISKS

  • Reimbursement: CPAP devices and masks are largely paid by insurers and government programs; rate cuts or stricter adherence rules hit volumes directly.
  • Competitive re-entry: Philips Respironics' return after its recall remediation could reverse the share ResMed gained since 2021.
  • GLP-1 demand debate: weight-loss drugs such as tirzepatide (approved for obstructive sleep apnea in December 2024) could shrink the untreated apnea pool over time — a live argument over the long-term diagnosis funnel.
  • Legal and compliance: in January 2020 ResMed paid $37.5M to settle U.S. False Claims Act and Anti-Kickback allegations over sleep and respiratory equipment support.
  • Manufacturing and currency: production concentrated in Australia, Singapore, France and the U.S. exposes margins to tariffs and exchange rates.

WHY IT MATTERS FOR THE S&P 500

ResMed is a small-weight health-care constituent: rank #314 by weight at 0.05% as of Nov 3, 2026, and #42 in Health Care. It is the index's dominant listed sleep-apnea franchise — a concentrated read on sleep and respiratory care and on out-of-hospital care software.

SOURCES & METHODOLOGY

Financials, segments, headquartersResMed fiscal 2026 Form 10-K data via StockAnalysis (year ended June 30, 2026) and the Form 10-K itself; headquarters, CEO and founding via Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights and market caps, fetched Nov 3, 2026 (intraday snapshot)
Market cap$31.59B (Nov 3, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

RMD

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號RMD
公司ResMed Inc.(瑞思邁)
GICS 板塊/行業醫療保健(XLV)/醫療保健設備
標普500排名(按權重)#314 · 0.05%(Nov 3, 2026)
板塊內排名醫療保健 #42(Nov 3, 2026)
總部美國加利福尼亞州聖地牙哥
成立1989年
執行長Michael「Mick」Farrell(執行長)
員工11,370(2026年)
市值$31.59B(Nov 3, 2026)
股價$223.92(Nov 3, 2026)
SEC 申報EDGAR — CIK 0000943819

業務概覽

瑞思邁總部位於美國加利福尼亞州聖地牙哥,是一家圍繞睡眠窒息症建立的數碼健康與醫療器械公司。公司生產用於在家診斷與治療睡眠呼吸障礙的 CPAP 與 APAP 呼吸機、面罩及雲端軟件,並透過旗下院外護理軟件(Residential Care Software)業務,為家居健康、善終服務與家居醫療設備供應商提供軟件平台。

其一句話商業模式是:向已確診的睡眠窒息人群出售設備與面罩,把設備全面聯網(每部設備均內置流動連接,數據回傳 AirView 與 myAir 平台),再疊加經常性軟件收入——2026 財年收入 56.5 億美元,分為設備(28.92 億美元)、面罩及其他配件(20.85 億美元)與院外護理軟件(6.76 億美元)。

瑞思邁於 1989 年 6 月由 Peter C. Farrell 在澳洲創立,把悉尼大學 Colin Sullivan 教授開創的 CPAP 療法商業化;1992 年於聖地牙哥設辦事處,1994 年把總部與註冊地遷往美國,並在紐交所與澳交所雙重上市。創辦人之子 Michael「Mick」Farrell 自 2013 年 3 月 1 日起任執行長。

業務板塊

設備CPAP/APAP 呼吸機與雙水平設備(AirSense 與 AirCurve 系列),屬睡眠與呼吸健康板塊——2026 財年收入 2,892 百萬美元。
面罩及其他病人介面(AirFit 面罩)、配件及其他睡眠與呼吸產品——2026 財年收入 2,085 百萬美元。
院外護理軟件供院外護理使用的 SaaS 平台——Brightree、MatrixCare 與 MEDIFOX DAN——獨立列作一個板塊;2026 財年收入 676 百萬美元。

瑞思邁申報兩個板塊——睡眠與呼吸健康(設備加面罩及其他,2026 財年合共 4,977 百萬美元)與院外護理軟件(676 百萬美元)。各產品線合計即 2026 財年總收入 5,653 百萬美元。

歷史沿革

年份里程碑
19891989 年 6 月由 Peter C. Farrell 在澳洲創立,把悉尼大學 Colin Sullivan 教授開創的持續正壓呼吸(CPAP)睡眠窒息療法商業化。
1992於加利福尼亞州聖地牙哥設辦事處(1992 年);1994 年總部遷往聖地牙哥並在美國註冊成立。公司維持紐交所與澳洲證券交易所雙重上市。
2013創辦人之子 Michael「Mick」Farrell 於 2013 年 3 月 1 日出任執行長。
2016以 8 億美元收購 Brightree,進入家居醫療設備供應商的軟件即服務領域——院外護理軟件板塊由此而生。
2020新冠疫情期間,瑞思邁轉產大規模生產呼吸機及其他呼吸設備(全球出貨數以十萬計)。
2022以約 10 億美元收購德國 MEDIFOX DAN 集團,把院外護理軟件擴展至歐洲。

競爭地位

  • 睡眠窒息品類領導地位:瑞思邁與 Philips Respironics 歷來主導 CPAP 設備與面罩市場;飛利浦自 2021 年起的多年召回令份額流向瑞思邁。
  • 聯網生態系統:設備內置流動連接,數據回傳 AirView 臨床平台與 myAir 病人應用,鎖定與家居醫療設備供應商的面罩續購與軟件關係。
  • 軟件多元化:院外護理軟件(Brightree、MatrixCare、MEDIFOX DAN)帶來較少受設備週期影響的 SaaS 收入——2026 財年 6.76 億美元。
  • 競爭對手:Philips Respironics、Fisher & Paykel Healthcare、Inspire Medical(植入式療法)及新進者;GLP-1 藥物是需求面的變數(見主要風險)。

財務快照

總收入$5.65B(FY2026 收入)
營業利潤$1,887M(FY2026 營業利潤)
淨利潤$1,523M(FY2026 淨利潤)
稀釋 EPS$10.43(FY2026 稀釋 EPS)
來源:瑞思邁 2026 財年業績(截至 2026 年 6 月 30 日)——StockAnalysis 財務數據(整理自 2026 財年 Form 10-K;產品線收入:設備、面罩及其他、院外護理軟件),員工人數經 Form 10-K 本身核對(2026 年 6 月 30 日約 11,370 人)。

主要風險

  • 報銷政策:CPAP 設備與面罩主要由保險公司與政府計劃支付;費率下調或依從性規定收緊將直接衝擊銷量。
  • 競爭對手回歸:Philips Respironics 在召回整改後重返市場,可能逆轉瑞思邁自 2021 年以來取得的份額。
  • GLP-1 需求爭議:替爾泊肽等減肥藥(2024 年 12 月獲批用於阻塞性睡眠窒息)長遠或縮小未治療的窒息人群——長期診斷渠道的影響是市場上持續的爭論。
  • 法律與合規:2020 年 1 月,瑞思邁支付 3,750 萬美元,就美國《虛假申報法》與《反回扣法》有關睡眠與呼吸設備支援的指控達成和解。
  • 生產與貨幣:生產集中於澳洲、新加坡、法國與美國,利潤率受關稅與匯率影響。

對標普500的重要性

瑞思邁是權重較小的醫療保健成分股:按權重排名 #314,權重 0.05%(以 Nov 3, 2026 為準),醫療保健板塊內排名 #42。它是指數中主導性的睡眠窒息上市企業,是觀察睡眠與呼吸健康及院外護理軟件的集中指標。

來源與方法

財務、板塊、總部瑞思邁 2026 財年 Form 10-K 數據,經 StockAnalysis(截至 2026 年 6 月 30 日)與 Form 10-K 本身;總部、執行長與創立經維基百科公司資料
指數權重與排名Slickcharts 標普500權重與市值,Nov 3, 2026 抓取(盤中快照)
市值$31.59B(Nov 3, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

RMD

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

月線共 119 根,涵蓋 2016 年 11 月至 2026 年 9 月。首根(2016 年 11 月)收市 $61.48;末根(2026 年 9 月)開市 $239.90、高 $242.40、低 $215.80、收市 $221.10。十年最高 $301.34(2021 年 9 月);十年最低 $56.59(2016 年 11 月)。

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · RMD
Data as of Nov 3, 2026 · Financials FY2026 (10-K) · Market data Nov 2026
Previous · Labcorp Holdings Inc. (LH) — XLV Health Care · S&P 500 Profile |拉伯克介紹Next · Centene Corporation (CNC) — XLV Health Care · S&P 500 Profile |Centene公司介紹

Entered 2026-11-03 10:58 · updated 2026-11-14 23:59 · rev 7